1.
American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Available at http://www.cancer.org
2.
Avril N,
Rose CA,
Schelling M,
et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
J Clin Oncol.
2000;18:3495–3502
3.Wahl RL,
Siegel BA,
Coleman RE,
et al.
Prospective multi-center study of axillary nodal staging with FDG positron emission tomography in breast cancer.
J Clin Oncol 2004;22:277–85
4.
Cermik TF,
Mavi A,
Basu S,
et al.
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Eur J Nucl Med Mol Imaging 2008; 35(3):475–83
5.
Carkaci S,
Macapinlac HA,
Ristofanilli M ,
et al. Retrospective study of 18 F–FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.
J Nucl Med.
2009;50(2):231–238
6.
Fuster D,
Duch J,
Paredes P,
et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
J Clin Oncol.
2008;26(29):4746–4751
7.
Vranjesevic,
D,
Filmont,
JE,
Meta,
J,
et al.
Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.
J Nucl Med 2002; 43:325
8.
Kamel,
EM,
Wyss,
MT,
Fehr,
MK,
et al.
[18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.
J Cancer Res Clin Oncol 2003; 129:147
9.
Isasi,
CR,
Moadel,
RM,
Blaufox,
MD.
A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.
Breast Cancer Res Treat 2005; 90-105